 DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 GLOBE NEWSWIRE -- Iterum Therapeutics plc Nasdaq: ITRM the Company, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of Americas IDWeek 2022. 